Albert Bourla, Pfizer CEO (Evan Vucci, AP Images)

Pfiz­er says it's ready to ramp up Paxlovid pro­duc­tion. Ex­perts say it's not that easy

Up­on the FDA’s au­tho­riza­tion of the first at-home Covid-19 pill to keep peo­ple out of the hos­pi­tal, Pfiz­er CEO Al­bert Bourla an­nounced his com­pa­ny has con­fi­dence it can make 120 mil­lion treat­ments in 2022, good for 3.6 bil­lion tablets.

The drug has peo­ple ex­cit­ed: Paxlovid was found to re­duce the risk of hos­pi­tal­iza­tion by 89% in tri­al with the same safe­ty pro­file as place­bo, Pfiz­er re­port­ed. Not a sin­gle per­son dosed with the oral an­tivi­ral in the tri­al died of Covid-19, while 10 pa­tients who re­ceived the place­bo did.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.